[go: up one dir, main page]

MX2023009921A - Formulaciones de proteinas de fusion ace2-fc. - Google Patents

Formulaciones de proteinas de fusion ace2-fc.

Info

Publication number
MX2023009921A
MX2023009921A MX2023009921A MX2023009921A MX2023009921A MX 2023009921 A MX2023009921 A MX 2023009921A MX 2023009921 A MX2023009921 A MX 2023009921A MX 2023009921 A MX2023009921 A MX 2023009921A MX 2023009921 A MX2023009921 A MX 2023009921A
Authority
MX
Mexico
Prior art keywords
ace2
fusion proteins
formulations
cov
sars
Prior art date
Application number
MX2023009921A
Other languages
English (en)
Inventor
Alwin Reiter
Rainer Sigl
Original Assignee
Formycon Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formycon Ag filed Critical Formycon Ag
Publication of MX2023009921A publication Critical patent/MX2023009921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas de proteínas de fusión ACE2-Fc y usos terapéuticos de las mismas, en particular en el tratamiento de infecciones por SARS-CoV-2.
MX2023009921A 2021-03-03 2022-03-03 Formulaciones de proteinas de fusion ace2-fc. MX2023009921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21160545 2021-03-03
PCT/EP2022/055457 WO2022184854A2 (en) 2021-03-03 2022-03-03 Formulations of ace2 fc fusion proteins

Publications (1)

Publication Number Publication Date
MX2023009921A true MX2023009921A (es) 2023-09-05

Family

ID=74858221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009921A MX2023009921A (es) 2021-03-03 2022-03-03 Formulaciones de proteinas de fusion ace2-fc.

Country Status (7)

Country Link
US (1) US20240139296A1 (es)
EP (1) EP4301333A2 (es)
JP (1) JP2024509543A (es)
AU (1) AU2022230745A1 (es)
CA (1) CA3205815A1 (es)
MX (1) MX2023009921A (es)
WO (1) WO2022184854A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115803091A (zh) * 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
EP4638729A1 (en) * 2022-12-23 2025-10-29 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
WO2025255596A1 (en) 2024-06-12 2025-12-18 Novabioma Biomanufacturing Flexco Isolated polypeptides comprising an ace2 moiety and a stability-increasing polypeptide moiety

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
CA2186455A1 (en) 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
DK1543106T3 (da) 2002-07-15 2007-08-13 Immunex Corp Fremgangsmåder og medier til kontrol af sialylering af proteiner, der dannes af mammaliaceller
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
WO2005032487A2 (en) 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
PL2235059T3 (pl) 2007-12-26 2015-08-31 Xencor Inc Warianty FC o zmodyfikowanym wiązaniu do FCRN
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
EP3470433B1 (en) 2012-04-27 2025-12-03 BioAtla, Inc. Modified antibody regions and uses thereof
SG11201703390SA (en) * 2014-10-27 2017-05-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
US20230075422A1 (en) 2019-12-20 2023-03-09 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
US12123036B2 (en) 2020-02-26 2024-10-22 Northwestern University Soluble ACE2 variants and uses therefor
EP4130047A4 (en) 2020-02-27 2024-07-31 Huahui Health Ltd. SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES
WO2021170113A1 (zh) 2020-02-29 2021-09-02 南京金斯瑞生物科技有限公司 ACE-2-Fc融合蛋白治疗冠状病毒的方法
WO2021183404A1 (en) 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
WO2021194909A1 (en) 2020-03-21 2021-09-30 Larix Biosciences, Llc Bispecific and trispecific functional molecules of ace2 and complement pathways and their use
CN113444710A (zh) 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202427A2 (en) 2020-03-29 2021-10-07 R-Pharm Overseas, Inc. Ace2-derived composition and use thereof
WO2021203098A2 (en) 2020-04-03 2021-10-07 The University Of North Carolina At Chapel Hill Binding proteins useful against ace2-targeted viruses
WO2021203103A2 (en) 2020-04-03 2021-10-07 Somasekar Seshagiri Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
US20230293647A1 (en) 2020-04-09 2023-09-21 Autolus Limited Polypeptide
CN113527510A (zh) 2020-04-22 2021-10-22 上海交通大学 融合蛋白分子及其制备方法和用途
WO2021213437A1 (zh) 2020-04-23 2021-10-28 上海复宏汉霖生物技术股份有限公司 ACE2-Fc融合蛋白及其应用
EP4138998A4 (en) 2020-04-24 2024-05-22 The Administrators of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the ace2 receptor
WO2021231466A2 (en) 2020-05-11 2021-11-18 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
CN115461078A (zh) 2020-05-11 2022-12-09 神州细胞工程有限公司 通过与改变的Fc片段形成融合蛋白增强蛋白/肽抗原免疫原性的方法
US20210386837A1 (en) 2020-05-18 2021-12-16 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
EP4168541A4 (en) 2020-05-20 2025-04-02 Emmune, Inc. Ace2 muteins and methods of using the same
CN115803091A (zh) 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
EP4165071A4 (en) 2020-06-15 2024-07-17 Academia Sinica HUMANIZED AC2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
AU2021297998A1 (en) 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
WO2022006601A1 (en) 2020-07-02 2022-01-06 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
WO2022012688A1 (en) 2020-07-17 2022-01-20 Shenzhen Bay Laboratory Ace2-ig fusion variants

Also Published As

Publication number Publication date
CA3205815A1 (en) 2022-09-09
WO2022184854A2 (en) 2022-09-09
AU2022230745A9 (en) 2024-07-18
JP2024509543A (ja) 2024-03-04
EP4301333A2 (en) 2024-01-10
AU2022230745A1 (en) 2023-08-17
US20240139296A1 (en) 2024-05-02
WO2022184854A3 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
PH12023550161A1 (en) Pharmaceutical composition and use thereof
PE20200303A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
EP4435007A3 (en) Trispecific proteins and methods of use
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
EP4230627A3 (en) Inhibitors of the menin-mll interaction
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
EP4338804A3 (en) Epinephrine spray formulations
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
GEP20257840B (en) Tyk2 pseudokinase ligands
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
SA522431748B1 (ar) طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
SA521420957B1 (ar) FXIa تركيبة جديدة ثابتة عالية التركيز لأجسام مضادة تعمل ضد
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.